Division of Paediatric Medicine, Department of Paediatrics, Faculty of Medicine.
Institute of Health Policy, Management and Evaluation.
Hosp Pediatr. 2022 Jan 1;12(1):70-89. doi: 10.1542/hpeds.2021-005910.
To examine the association between systemic corticosteroid use and outcomes for children hospitalized with orbital cellulitis at US children's hospitals.
We conducted a multicenter observational study using administrative data from the Pediatric Health Information System database from 2007 to 2019. Children between the ages of 2 months and 18 years with International Classification of Diseases, Ninth Revision, Clinical Modification or 10th Revision, Clinical Modification discharge diagnostic codes of orbital cellulitis were included. The primary exposure was receipt of systemic corticosteroids on the day of hospital admission. The primary outcome was hospital length of stay, and secondary outcomes included surgical intervention, ICU admissions, revisits, and health care costs. We used generalized logit model with inverse probability weighting logistic regression to adjust for demographic factors and assess for differences in clinical outcomes reported.
Of the 5832 patients hospitalized with orbital cellulitis, 330 (5.7%) were in the corticosteroid group and 5502 (94.3%) were in the noncorticosteroid group. Patients in the corticosteroid group were older, had more severe illness, and received broad spectrum antibiotics. In adjusted analyses, corticosteroid exposure was not associated with differences in length of hospital stay, need for surgical intervention, ICU admissions, emergency department revisits, 30-day hospital readmissions, or hospital costs. Restricting the analysis to only those patients who received broad spectrum antibiotics did not change the findings.
Early use of systemic corticosteroids in hospitalized children with orbital cellulitis is not associated with improved clinical outcomes. Use of corticosteroids in hospitalized children with orbital cellulitis should be discouraged outside of clinical trials.
研究美国儿童医院因眶蜂窝织炎住院的儿童使用全身性皮质类固醇与结局的关系。
我们使用 2007 年至 2019 年期间儿科健康信息系统数据库的行政数据进行了一项多中心观察性研究。年龄在 2 个月至 18 岁之间、国际疾病分类第 9 版临床修订版或第 10 版临床修订版出院诊断代码为眶蜂窝织炎的患儿纳入研究。主要暴露因素为入院当天接受全身性皮质类固醇治疗。主要结局为住院时间,次要结局包括手术干预、入住重症监护病房、复诊和医疗费用。我们使用广义逻辑模型和逆概率加权逻辑回归来调整人口统计学因素,并评估报告的临床结局差异。
在 5832 例因眶蜂窝织炎住院的患者中,330 例(5.7%)接受皮质类固醇治疗,5502 例(94.3%)未接受皮质类固醇治疗。皮质类固醇组患者年龄较大,病情较重,接受广谱抗生素治疗。在调整分析中,皮质类固醇暴露与住院时间、手术干预需求、入住重症监护病房、急诊科复诊、30 天内再住院或住院费用无差异。仅对接受广谱抗生素治疗的患者进行分析,结果并未改变。
眶蜂窝织炎住院患儿早期使用全身性皮质类固醇不能改善临床结局。眶蜂窝织炎住院患儿使用皮质类固醇应在临床试验之外受到限制。